Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms.

Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms.

Vaccine efficacy (VE) estimates are crucial for assessing the suitability of dengue vaccine candidates for public health implementation, but efficacy trials are subject to a known bias to estimate VE toward the null if heterogeneous exposure is not accounted for in the analysis of trial data. In lig...

Full description

Bibliographic Details
Main Authors: Guido España, Cosmina Hogea, Adrienne Guignard, Quirine A Ten Bosch, Amy C Morrison, David L Smith, Thomas W Scott, Alexander Schmidt, T Alex Perkins
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0210041

Internet

https://doi.org/10.1371/journal.pone.0210041

Similar Items